• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gossamer Bio Inc (NQ: GOSS )

    0.9900 +0.0300 (+3.13%)
    Streaming Delayed Price Updated: 9:31 AM EDT, Sep 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Gossamer Bio Inc

    < Previous 1 2 Next >
    Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces $212 Million Private Placement Financing
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces $120 Million Private Placement Financing
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH
    From Gossamer Bio, Inc.
    Via Business Wire
    Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.